|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
WO2020085504A1
(ja)
|
2018-10-26 |
2020-04-30 |
大鵬薬品工業株式会社 |
光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
CA3191279A1
(en)
|
2020-08-28 |
2022-03-03 |
Yi Liu |
Heterocyclic compounds and uses thereof
|
|
CA3203080A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Hongqi Tian |
Preparation and application method of heterocyclic compound as kras inhibitor
|
|
JP2024510207A
(ja)
*
|
2021-03-12 |
2024-03-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｋｒａｓ阻害剤
|
|
CN117659051A
(zh)
*
|
2021-03-30 |
2024-03-08 |
上海德琪医药科技有限公司 |
Kras g12d蛋白抑制剂和其用途
|
|
US20250059205A1
(en)
*
|
2021-04-29 |
2025-02-20 |
Amgen Inc. |
Heterocyclic Compounds and Methods of Use
|
|
MX2023012725A
(es)
*
|
2021-04-29 |
2024-09-23 |
Amgen Inc |
Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
|
|
US20230391785A1
(en)
*
|
2021-05-24 |
2023-12-07 |
280 Bio, Inc. |
Nitrogen-containing heterocyclic compound, method for preparing same and use of same
|
|
WO2023284881A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as kras g12d inhibitors
|
|
UY39906A
(es)
*
|
2021-08-18 |
2023-03-31 |
Jacobio Pharmaceuticals Co Ltd |
Derivados de 1,4-oxazepano y usos de los mismos
|
|
US20240409558A1
(en)
*
|
2021-09-13 |
2024-12-12 |
Biomea Fusion, Inc. |
Irreversible inhibitors of kras
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
WO2023072188A1
(zh)
*
|
2021-10-29 |
2023-05-04 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
EP4436571A4
(en)
*
|
2021-11-24 |
2025-10-15 |
Merck Sharp & Dohme Llc |
SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS
|
|
US20250250286A1
(en)
*
|
2021-11-30 |
2025-08-07 |
Beta Pharma, Inc. |
Fused pyrimidine derivatives as kras oncoprotein inhibitors
|
|
WO2023114733A1
(en)
*
|
2021-12-13 |
2023-06-22 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2023137223A1
(en)
*
|
2022-01-17 |
2023-07-20 |
Newave Pharmaceutical Inc. |
Pan-kras inhibitors and uses thereof
|
|
CN118556063A
(zh)
*
|
2022-01-21 |
2024-08-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
AU2023216698A1
(en)
*
|
2022-02-03 |
2024-06-13 |
Mirati Therapeutics, Inc. |
Quinazoline pan-kras inhibitors
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
MX2024010045A
(es)
*
|
2022-02-16 |
2024-08-26 |
Amgen Inc |
Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras.
|
|
JP2025510572A
(ja)
|
2022-03-08 |
2025-04-15 |
レボリューション メディシンズ インコーポレイテッド |
免疫不応性肺癌を治療するための方法
|
|
AU2023231139A1
(en)
|
2022-03-11 |
2024-09-05 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2023215802A1
(en)
*
|
2022-05-04 |
2023-11-09 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN117327102B
(zh)
*
|
2022-06-30 |
2026-04-28 |
重庆华森英诺生物科技有限公司 |
Kras抑制剂、其制备方法及应用
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
WO2024008179A1
(en)
*
|
2022-07-07 |
2024-01-11 |
Beigene, Ltd. |
Heterocyclic compounds, compositions thereof, and methods of treatment therewith
|
|
IL318647A
(en)
|
2022-08-05 |
2025-03-01 |
Kumquat Biosciences Inc |
Heterocyclic compounds and their uses
|
|
WO2024041606A1
(zh)
*
|
2022-08-24 |
2024-02-29 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
US20260083750A1
(en)
*
|
2022-08-26 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2024045066A1
(en)
*
|
2022-08-31 |
2024-03-07 |
Nikang Therapeutics, Inc. |
Alkylidene carbamate as kras inhibitors
|
|
EP4584276A1
(en)
*
|
2022-09-07 |
2025-07-16 |
Bristol-Myers Squibb Company |
Kras g12d inhibitors
|
|
WO2024054625A2
(en)
*
|
2022-09-08 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
|
|
TW202416976A
(zh)
*
|
2022-09-16 |
2024-05-01 |
大陸商南京明德新藥研發有限公司 |
含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物
|
|
WO2024061365A1
(zh)
*
|
2022-09-22 |
2024-03-28 |
成都奥睿药业有限公司 |
嘧啶并环类化合物及其制备方法与用途
|
|
WO2024063576A1
(ko)
*
|
2022-09-23 |
2024-03-28 |
일동제약(주) |
Kras 저해 물질로서 신규한 퀴나졸린 화합물
|
|
JP2025536369A
(ja)
|
2022-10-21 |
2025-11-05 |
リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド |
Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
|
|
EP4631942A1
(en)
|
2022-10-21 |
2025-10-15 |
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. |
Pan-kras degrading agent, and preparation method therefor and use thereof
|
|
TW202430179A
(zh)
|
2022-11-21 |
2024-08-01 |
美商樹線生物科學公司 |
螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
KR20260041941A
(ko)
|
2023-03-15 |
2026-03-27 |
콴타 테라퓨틱스, 인크. |
Kras 조절 인자 및 이의 용도
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CN118772151A
(zh)
*
|
2023-04-04 |
2024-10-15 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CR20250420A
(es)
|
2023-04-07 |
2025-11-20 |
Revolution Medicines Inc |
Inhibidores macrocíclicos de ras
|
|
CN121100123A
(zh)
|
2023-04-14 |
2025-12-09 |
锐新医药公司 |
Ras抑制剂的结晶形式
|
|
CN121464140A
(zh)
|
2023-04-14 |
2026-02-03 |
锐新医药公司 |
Ras抑制剂的结晶形式、含有其的组合物及其使用方法
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
CN121532183A
(zh)
*
|
2023-05-15 |
2026-02-13 |
米拉蒂治疗公司 |
Kras g12s和g12c抑制剂
|
|
WO2025019823A1
(en)
*
|
2023-07-20 |
2025-01-23 |
Merck Sharp & Dohme Llc |
Small molecule protein degraders of kras g12d mutant
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025038936A1
(en)
|
2023-08-17 |
2025-02-20 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
AU2024337016A1
(en)
*
|
2023-09-08 |
2026-04-16 |
Tyligand Bioscience (Shanghai) Limited |
Ras inhibitor
|
|
TW202528315A
(zh)
|
2023-09-21 |
2025-07-16 |
美商樹線生物科學公司 |
螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
TW202545934A
(zh)
*
|
2024-02-05 |
2025-12-01 |
日商安斯泰來製藥股份有限公司 |
包含具有突變ｋｒａｓ蛋白分解誘導作用之雜環化合物的抗體藥物複合體
|
|
WO2025170938A1
(en)
*
|
2024-02-06 |
2025-08-14 |
Windermere Therapeutics, Inc. |
Kras(g12d) inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025218811A1
(zh)
*
|
2024-04-19 |
2025-10-23 |
领泰生物医药(绍兴)有限公司 |
pan-KRAS靶向蛋白降解剂及其制备方法和应用
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025245127A1
(en)
|
2024-05-21 |
2025-11-27 |
Treeline Biosciences, Inc. |
Spirocyclic dihydropyranopyrimidine kras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|